Radiopharmaceutical developer CereMark announced that additional patents have been awarded to the University of California, Los Angeles (UCLA) for a PET agent that the company licensed from the university for the imaging of Alzheimer's disease.
The patents are associated with F-18 flornaptitril (also known as F-18 FDDNP), a biomarker for the detection, development, and progression of Alzheimer's disease, as well as chronic traumatic encephalopathy and other neurodegenerative diseases.
The patents cover a synthesizing method that allows for high radiochemical yields and short manufacturing times for administration.
CereMark is UCLA's only licensee for the development and commercialization of F-18 flornaptitril, and the company is preparing for a phase 3 clinical multisite study required for U.S. Food and Drug Administration approval.
